Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

Publisher： Karger

E-ISSN： 1423-0232|92|4|205-212

ISSN： 0030-2414

Source： Oncology, Vol.92, Iss.4, 2017-02, pp. : 205-212

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 40, Iss. 1-2, 2017-01 ,pp. : 21-26

Karger

Access to resources Recommend Favorite

Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 67-71

Karger

Access to resources Recommend Favorite

Single-Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Pathway and Outcomes of Patients Treated with First-Line Cytotoxic Chemotherapy Combined with Bevacizumab for Advanced Colorectal Cancer

By  

Oncology, Vol. 87, Iss. 5, 2014-08 ,pp. : 280-292

Karger

Access to resources Recommend Favorite

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4290-4298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients

By  

Oncology, Vol. 83, Iss. 2, 2012-07 ,pp. : 101-107

Karger

Access to resources Recommend Favorite